Status: Planned
First registered on:
30/05/2018
Last updated on:
01/06/2018
1. Study identification
EU PAS Register NumberEUPAS24224
Official titlePATTERN OF USE AND SAFETY PROFILE OF BRANDED VS GENERIC ANTIEPILEPTIC DRUGS
Study title acronym
Study typeObservational study
Brief description of the study
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsUADRM
Department/Research groupUnit of adverse drug reactions monitoring
Organisation/affiliationUniversity hospital of Pisa
Details of (Primary) lead investigator
Title Dr
Last name Lucenteforte
First name Ersilia
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?3
Countries in which this study is being conducted
National study
Italy
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed01/06/2018
Start date of data collection01/06/2018
Start date of data analysis11/06/2018
Date of interim report, if expected
Date of final study report28/09/2018
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherUniversity of Florence100
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Lucenteforte
First name Ersilia
Address line 1via Savi 10
Address line 2
Address line 3
CityPisa
Postcode56126
CountryItaly
Phone number (incl. country code)39-050-2218285
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Lucenteforte
First name Ersilia
Address line 1via Savi 10
Address line 2
Address line 3
CityPisa
Postcode56126
CountryItaly
Phone number (incl. country code)39-050-2218285
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)N03 (ANTIEPILEPTICS)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Children (2 - 11 years)
Adolescents (12 - 17 years)
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
Other population
Renal impaired
Hepatic impaired
Immunocompromised
Pregnant women
9. Number of subjects
Estimated total number of subjects30000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Administrative database, e.g. claims database
11. Scope of the study
What is the scope of the study?
Risk assessment
Drug utilisation study
Primary scope : Drug utilisation study
12. Main objective(s)
What is the main objective of the study?
- describe the therapeutic pattern of generic vs branded antiepileptics (AEDs).
- assess the risk profile of generic vs branded AEDs .
-to describe the most frequent AEDs- related ADRs among users of generic vs branded AEDs.
Are there primary outcomes?Yes
All hospitalization and/or access to ED occurring during follow-up.
Are there secondary outcomes?Yes
All hospitalization and/or access to ED occurring during follow-up with a diagnosis of possible AEDs-related ADRs in primary or secondary diagnosis field.
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
From the index date (first AED prescription) until the first date between: i) end of study period (365 days after index date), ii) death, iii)prescription of an AEDs with a different ATC code, iv) prescription records and/or hospitalizations related to neoplasia, v) outcome or vi) patient’s exit from databases.
15. Data analysis plan
Please provide a brief summary of the analysis method
- Descriptive analysis will be used to describe the most frequently prescribed active principles and exposure classes, proportions of switching, and the most frequent AEDs- related ADRs.
- Propensity Score (PS) calculation: we will use PS matching to balance the baseline characteristics between subjects treated with brand vs generic AEDs. PS will be calculated on demographic, socio-economic and clinical variables, using the Stata routine PSmatch2 to perform nearest number matching with a caliper of 0.2. of the SD of PS.
- Statistical analysis: Adjusted Cox regression models will be fitted to estimate the risk of hospitalization and/or access to ED for any cause and for AEDs-related ADRs among subjects exposed to generic vs branded AEDs. Analysis will be stratified according to different ATC codes.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Available when the study ends
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
